News
AXELPHEX™ Featured in Saisachi Interview
AXELPHEX™, a nucleic acid pharmaceutical API CRDMO service jointly operated by Mitsubishi Gas Chemical Company, Inc. (MGC) and Hokkaido System Science Co., Ltd. (HSS), has been featured in an interview article in Saisachi, an information platform covering research and life sciences.
The article introduces the background behind the launch of AXELPHEX™, our CRDMO services for nucleic acid drug development, and our vision for the future.
■ Featured Article:
- Saisachi“Accelerating the Social Implementation of Nucleic Acid Therapeutics with AXELPHEX™ — The Future of an Evolving CRDMO”
Published September 30, 2026 - Website: https://saisachi.com/interview13_axelphex_english/